Category: Latest News
-
Crinetics Shares Jump on Robust PALSONIFY Uptake and Encouraging Trial Results
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) shares rallied 19% after the company reported a strong early commercial performance for PALSONIFY alongside favorable clinical data for its congenital adrenal hyperplasia (CAH) pipeline program. The San Diego–based endocrine specialist said unaudited, preliminary net product revenue for PALSONIFY exceeded $5 million in the fourth quarter of 2025, marking the drug’s…
-
Momentus Shares Spike After Advancing 3D-Printed Fuel Tank for Spaceflight
Momentus Inc. (NASDAQ:MNTS) shares jumped 44.1% in premarket trading on Monday after the company disclosed progress on a newly developed 3D-printed fuel tank created in partnership with Velo3D. The U.S.-based commercial space company said the additively manufactured tank is slated for flight testing on its upcoming Vigoride-7 Orbital Service Vehicle mission. The component was produced…
-
Skye Bioscience Shares Rise on Halozyme Partnership to Advance Obesity Treatment
Skye Bioscience Inc. (NASDAQ:SKYE) shares gained 5.3% in premarket trading on Monday after the company revealed a collaboration with Halozyme Therapeutics (NASDAQ:HALO) to develop a subcutaneous version of its obesity drug candidate, nimacimab. The non-exclusive, worldwide collaboration and licensing agreement, signed in December 2025, gives Skye access to Halozyme’s ENHANZE drug delivery technology. The partnership…
-
Okta Shares Edge Higher After Unveiling $1 Billion Buyback Plan
Okta Inc. (NASDAQ:OKTA) shares rose 1.8% in premarket trading on Monday after the identity security specialist announced the launch of a $1 billion share repurchase program. The authorization, which takes effect immediately, signals management’s confidence in Okta’s outlook and its view that the company’s stock does not fully reflect underlying value, according to a statement.…
-
RedHill Biopharma Shares Jump on Progress Toward Treating GLP-1 Side Effects
RedHill Biopharma Ltd. (NASDAQ:RDHL) shares climbed 16.5% in premarket trading on Monday after the company reported advances in the development of RHB-102 (Bekinda), a therapy aimed at addressing gastrointestinal side effects linked to widely used GLP-1/GIP weight-loss and diabetes drugs. The specialty biopharmaceutical group is progressing RHB-102—a once-daily oral formulation of ondansetron—through the U.S. Food…
-
Marcus Lemonis Steps Into CEO Role as Bed Bath & Beyond Accelerates Expansion
Bed Bath & Beyond Inc. (NYSE:BBBY) said that Marcus Lemonis has been appointed Chief Executive Officer, adding the role to his existing position as Executive Chairman of the Board. The Murray, Utah–based company highlighted a marked improvement in its financial performance during the third quarter of 2025. Net losses narrowed by more than 90% year…
-
Arbe Robotics Shares Surge After Introducing NVIDIA-Backed Radar Platform
Arbe Robotics Ltd. (NASDAQ:ARBE) shares jumped 20.8% in premarket trading on Monday after the company unveiled a new radar platform that integrates its proprietary technology with computing solutions from NVIDIA (NASDAQ:NVDA). The Israel-based provider of perception radar systems said it will present the automotive-grade platform at CES 2026, highlighting its readiness to be incorporated into…
-
Ambarella Shares Edge Higher After Debut of CV7 Edge AI Chip at CES
Ambarella Inc. (NASDAQ:AMBA) shares rose 2.5% in premarket trading on Monday after the company introduced its new CV7 edge AI vision system-on-chip at the CES technology show. The newly unveiled semiconductor targets advanced AI perception workloads across a range of applications, including consumer electronics, security cameras, robotics and automotive systems. Ambarella said the CV7 is…
-
Datavault AI Shares Surge on Nationwide SanQtum Rollout With AP Global
Datavault AI Inc. (NASDAQ:DVLT) shares jumped 25.6% in premarket trading on Monday after the company unveiled plans for a nationwide rollout of SanQtum infrastructure through a partnership with AP Global Holdings LLC. The AI-focused data valuation group said it has signed a Master Purchase Order Agreement with AP Global Holdings, which operates under the name…
-
Altimmune Shares Rally After FDA Awards Breakthrough Status to Pemvidutide
Altimmune (NASDAQ:ALT) shares jumped 14% on Monday after the company said its liver disease candidate pemvidutide had been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The designation, designed to speed the development and regulatory review of therapies that may offer meaningful advantages over…